» Articles » PMID: 37025206

Case Report: Radiographic Complete Response of Radiation-induced Glioblastoma to Front-line Radiotherapy: A Report and Molecular Characterization of Two Unique Cases

Overview
Journal Front Neurol
Specialty Neurology
Date 2023 Apr 7
PMID 37025206
Authors
Affiliations
Soon will be listed here.
Abstract

Radiation-induced gliomas (RIGs) are an uncommon disease type and a known long-term complication of prior central nervous system radiation exposure, often during childhood. Given the rarity of this malignancy subtype, no clinical trials have explored optimal therapy for these patients, and the literature is primarily limited to reports of patient cases and series. Indeed, the genomic profiles of RIGs have only recently been explored in limited numbers, categorizing these gliomas into a unique subset. Here, we describe two cases of RIG diagnosed as glioblastoma (GB), IDH-wildtype, in adults who had previously received central nervous system radiation for childhood cancers. Both patients demonstrated a surprising complete radiographic response of the postoperative residual disease to front-line therapy, a phenomenon rarely observed in the management of any GB and never previously reported for the radiation-induced subgroup. Both tumors were characterized by next-generation sequencing and chromosomal microarray to identify potential etiologies for this response as well as to further add to the limited literature about the unique molecular profile of RIGs, showing signatures more consistent with diffuse pediatric-type high-grade glioma, -wildtype, and IDH-wildtype, WHO grade 4. Ultimately, we demonstrate that treatment utilizing a radiation-based regimen for GB in a previously radiated tissue can be highly successful despite historical limitations in the management of this disease.

Citing Articles

A patient with heterochronous double primary tumor of basal ganglia germ cell tumors followed by diffuse hemispheric glioma: a case report.

He Z, Jiang X, Wang Z, Luo N, Song Y Childs Nerv Syst. 2024; 40(12):4315-4321.

PMID: 39466461 DOI: 10.1007/s00381-024-06644-w.


Clinical and molecular study of radiation-induced gliomas.

Trkova K, Sumerauer D, Bubenikova A, Krskova L, Vicha A, Koblizek M Sci Rep. 2024; 14(1):3118.

PMID: 38326438 PMC: 10850080. DOI: 10.1038/s41598-024-53434-0.

References
1.
DeSisto J, Lucas Jr J, Xu K, Donson A, Lin T, Sanford B . Comprehensive molecular characterization of pediatric radiation-induced high-grade glioma. Nat Commun. 2021; 12(1):5531. PMC: 8452624. DOI: 10.1038/s41467-021-25709-x. View

2.
Liu Q, Turner K, Yung W, Chen K, Zhang W . Role of AKT signaling in DNA repair and clinical response to cancer therapy. Neuro Oncol. 2014; 16(10):1313-23. PMC: 4165418. DOI: 10.1093/neuonc/nou058. View

3.
Yi G, Huang G, Guo M, Zhang X, Wang H, Deng S . Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2. Brain. 2019; 142(8):2352-2366. PMC: 6658867. DOI: 10.1093/brain/awz202. View

4.
Wu D, Chen B, Parihar K, He L, Fan C, Zhang J . ERK activity facilitates activation of the S-phase DNA damage checkpoint by modulating ATR function. Oncogene. 2005; 25(8):1153-64. DOI: 10.1038/sj.onc.1209148. View

5.
Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View